Time between medicine authorization and patient access in Europe 2024, by country

Patient access is defined for most countries as the point at which the product gains access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme.
* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not take into account France's system of temporary authorization for some products, which means this time will be higher than in reality.
***MHRA’s Early Access to Medicines Scheme provides access prior to marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.